{
    "nct_id": "NCT05804318",
    "official_title": "Daily Adaptive Stereotactic Body Radiation Therapy for Prostate Cancer With Urethral Sparing: A Prospective Trial Using an Individualized Approach to Reduce Urinary Toxicity",
    "inclusion_criteria": "1. Patient has NCCN low or intermediate risk prostate cancer that is biopsy proven.\n2. Prostate volume is ≤80cc as assessed by MRI prior to radiotherapy.\n3. AUA/IPSS score is ≤ 15.\n4. ECOG performance status is ≤2 (or Karnofsky score is ≥60%).\n5. Patient has no PIRADS 4 or 5 lesion on prostate MRI contacting the urethra (determined at physician discretion).\n6. Patient has the ability to complete required patient questionnaires.\n7. Patient age ≥ 18 years (or greater than the local age of majority).\n8. Patient has the ability to understand and the willingness to sign a written informed consent document.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Patient has baseline grade ≥3 GI or GU toxicity\n2. Patient has had prior overlapping pelvic radiotherapy.\n3. Patient has had prior transurethral resection of the prostate, prostate HIFU, or cryoablation.\n4. Patient has node positive prostate cancer.\n5. Patient has extracapsular extension (capsular abutment is permitted).\n6. Patient has active inflammatory bowel disease or active collagen vascular disease.\n7. Patient cannot undergo prostate MRI.\n8. Patient cannot undergo prostate fiducial marker placement.\n9. Patient has ongoing receipt of cytotoxic chemotherapy (androgen deprivation therapy is allowed).",
    "miscellaneous_criteria": ""
}